Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma

We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow. The first patient had progressive disease 18 months post autologous peripheral stem cell transplant. Two and a half mont...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2001, Vol.42 (4), p.683-687
Main Authors: Avigdor, Abraham, Raanani, Pia, Levi, Itai, Hardan, Izhar, Ben-Bassat, Isaac
Format: Article
Language:English
Subjects:
adhesion molecules
Adult
Bone Marrow - pathology
Bone Marrow Neoplasms - pathology
Brain Neoplasms - pathology
Disease Progression
extramedullary plasmacytoma
Humans
Male
Middle Aged
multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Nasal Mucosa - pathology
Nose Neoplasms - pathology
Plasmacytoma - pathology
resistant
Skin Neoplasms - pathology
thalidomide
Thalidomide - administration & dosage
Thalidomide - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow. The first patient had progressive disease 18 months post autologous peripheral stem cell transplant. Two and a half months after the initiation of thalidomide therapy extensive new plasmacytomas of the skin and nasal mucosa appeared while the medullary response continued. The second patient was treated with thalidomide for resistant MM. Despite a medullary response he developed neurological signs compatible with cranial nerve involvement and an MRI study was suggestive of a plasmacytoma involving the sellar region. We assume that a change in the expression of some adhesion molecules on the myeloma and/or the stromal cells is responsible for this phenomenon. Treating Physicians should be aware of this phenomenon in MM patients receiving thalidomide.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428190109099330